Background: Despite recent progress in diagnostic and oncology therapy, lung cancer constitutes the leading cause of cancer-associated mortality worldwide, with approximately 85% of lung cancer cases being nonesmall cell lung cancer (NSCLC) histological type. The study of epidermal growth factor receptor (EGFR) gene mutational profile in nonesmall cell lung cancer patients has a special clinical significance in the selection of patients for tyrosine-kinase inhibitor therapy. The aim of this study was to identify the frequency and spectrum of EGFR mutations in a cohort of Moroccan patients with lung cancer using the ADx-ARMS technology. Method: We performed a retrospective study by processing 164 cases of NSCLC patients recruited between March 2015 and March 2018. Using the DNA extracted from the formalin-fixed paraffin-embedded FFPE tissue, we attempted to identify somatic mutations in exons 18 to 21 of the tyrosine-kinase "TK" domain of EGFR gene. We evaluated EGFR mutations using High Resolution Melt (HRM) polymerase chain reaction (PCR) and real time PCR "ADx-ARMS technology" for results confirmation. Results: Among the positive mutant cases, the resulting mutations were as follows: 70% of patients have a deletion in exon 19, 10% in exon 21(L858R), 10% in exon 20 (6.7% T790M and 3.3% S768L) and 10% in exon 18 (G719A/C). The EGFR mutations were more frequent among males compared to females (51,7% and 48,3% respectively), all of the positive patients with EGFR mutations were adenocarcinoma (ADK) and 37,9%% of them were smokers. Conclusion: The presented method can be implemented at the laboratories to identify the most frequent EGFR mutations that are important for targeted therapy of advanced lung cancer patients. Background: Small cell lung cancer (SCLC) accounts for about 10%-15% of the total number of lung cancer and with a poor outcome. Especially in extensive-stage (ED) small cell Lung Cancer, the 5-year survival rate is less than 5%. To improve the survival outcome, a number of therapeutic approaches have been tried, such as dose dense chemotherapy, high-dose chemotherapy, maintenance therapy and consolidation chemotherapy. However, the result was of no proven benefit. Patients with a lower pretreatment circulating VEGF levels were more likely to respond to chemotherapy compared to those with higher levels of VEGF. The results from these studies suggest that VEGF may be linked to overall poor outcome in SCLC. Therefore, inhibition of VEGF represents a rational therapeutic strategy for evaluation in SCLC. Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2). Although there have been few studies of small cell Lung Cancer treated with apatinib so far, a retrospective study showed that apatinib exhibits modest activity and acceptable toxicity for the heavily pretreated patients with extensive-stage SCLC. The disease control rate was 81.8%. However, is there a benefit in survival of apatinib as maintenance therapy in extensive-stage SCLC is unclear. Therefore, the aim of this study was to analyze the efficacy and safety of apatinib as maintenance therapy in extensive-stage SCLC. Method: Retrospective analysis of 23 cases extensive-stage SCLC that admitted to The Affiliated Cancer Hospital of Zhengzhou University from January 2015 to December 2017. The patients without progression after induction chemotherapy, received apatinib 250mg per day until disease progression or unacceptable toxicity occurs. We analyzed the median progression-free survival (PFS), median Overall survival (OS) and safety. Results: Of 23 enrolled patients,1 was lost to follow-up. The median PFS from the time of maintenance therapy was 4.1 months (95%CI,3.63 to 4.57 months). The median PFS from the time of induction chemotherapy was 8.3 months (95%CI,7.20 to 9.40 months). The median OS from the time of maintenance therapy was 12.5 months (95%CI,5.51 to 19.49 months). The median OS from the time of induction chemotherapy was 17.0 months (95%CI,9.86 to 24.14 months). The most frequent treatmentrelated adverse events were hand-foot syndrome (43.5%, 10/23), secondary hypertension (30.4%, 7/23). Fatigue, proteinuria, nausea, oral mucositis were 17.4%, 13.0%, 13.0%, 8.7%, respectively. Hematologic toxicity includes thrombocytopenia (30.4%), leucopenia (26.1%), and anemia (17.4%). Main grade 3 or 4 toxicities were hand-foot syndrome (8.7%, 2/23), and hypertension (4.3%, 1/23 Background: Lung cancer is the most common cause of death from cancer worldwide, estimated to be responsible 1.59 million deaths, representing 19.4% of all cancer types. Representing 80e85% of all cases nonesmall cell lung cancer (NSCLC) is the most predominant type of lung cancer. Lung cancer has been recognized as a complex multifactorial disease resulting from the interactions between various genetic and environmental factors. Identification of genes involved in the occurrence and development of lung cancer could contribute to further understanding of the underlying mechanisms, and even a very important additional appropriate prevention strategies and targeted treatments for reducing lung cancer burden. Many studies have suggested that key cytokines in inflammation pathways may exert important roles in the etiology of lung cancer. The aim of this study was to investigate whether common variants in inflammatory and immune response genes influence lung cancer risk in Moroccan patients. Method: Using a candidate gene approach, 6 single nucleotide polymorphisms (SNPs) in 4 genes were assessed in 117controls and 117 lung cancer patients. Genotyping was performed with the TaqMan® allelic discrimination technology. The results were analysed using SPSS 24.0 software. Results: Among the 5 studied genes, we found a significant association for the MIF (rs755622) (OR¼1.63; 95% confidence interval 1.04-2.56; p ¼0.03), IL-6 (rs2069840) (OR¼1.63; 95% confidence interval 1.08-2.47; p ¼0.01) and STAT3. No significant association was observed for the remaining SNPs in the following genes: IL17A rs7747909, IL-6R_rs2228145, IL6ST_rs2228044. Background: More than 50% of advanced NSCLC patients are older than 65 years old (y), with a median age at diagnosis of 68 y. This group of patients have been usually underrepresented in clinical trials. The aim of our study is to compare whether clinical characteristics, toxicity, response rate, overall survival (OS), and progression free survival (PFS) are different in p > 70y vs. < 70y, treated with platinum based chemotherapy. Method: We reviewed the database of the Instituto Oncologico Córdoba, Argentina (IONC). Survival curves were made up by Kaplan-Maier method and compared using the log-rank test. Results: Out of 198 p; 103 p (52 %) < 70y, and 95 p (48 %) > 70y We found significant differences in OS (9.4 vs. 7.5 months, p¼0.003) and PFS (6.4 vs. 5.1 months, p¼0.002) Significant differences in OS were also found between the two groups regarding anemia, Performance status (PS) and response rate with no difference on sex and histology. Conclusion: Significant differences in OS and PFS were evident between both groups. We observed increased toxicity in p > 70y, but without greater treatment-related mortality. OS and PFS were superior in patients treated with platinum-based doublets when compared to monotherapy (according to historical records); therefore we should choose the former in elderly patients. Keywords: Treatment of advanced, Lung cancer, nonesmall cell lung cancer (NSCLC), older than 70
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The Background: Small cell lung cancer (SCLC) accounts for about 10%-15% of the total number of lung cancer and with a poor outcome. Especially in extensive-stage (ED) small cell Lung Cancer, the 5-year survival rate is less than 5%. To improve the survival outcome, a number of therapeutic approaches have been tried, such as dose dense chemotherapy, high-dose chemotherapy, maintenance therapy and consolidation chemotherapy. However, the result was of no proven benefit. Patients with a lower pretreatment circulating VEGF levels were more likely to respond to chemotherapy compared to those with higher levels of VEGF. The results from these studies suggest that VEGF may be linked to overall poor outcome in SCLC. Therefore, inhibition of VEGF represents a rational therapeutic strategy for evaluation in SCLC. Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2). Although there have been few studies of small cell Lung Cancer treated with apatinib so far, a retrospective study showed that apatinib exhibits modest activity and acceptable toxicity for the heavily pretreated patients with extensive-stage SCLC. The disease control rate was 81.8%. However, is there a benefit in survival of apatinib as maintenance therapy in extensive-stage SCLC is unclear. Therefore, the aim of this study was to analyze the efficacy and safety of apatinib as maintenance therapy in extensive-stage SCLC. Method: Retrospective analysis of 23 cases extensive-stage SCLC that admitted to The Affiliated Cancer Hospital of Zhengzhou University from January 2015 to December 2017. The patients without progression after induction chemotherapy, received apatinib 250mg per day until disease progression or unacceptable toxicity occurs. We analyzed the median progression-free survival (PFS), median Overall survival (OS) and safety. Background: Lung cancer is the most common cause of death from cancer worldwide, estimated to be responsible 1.59 million deaths, representing 19.4% of all cancer types. Representing 80e85% of all cases nonesmall cell lung cancer (NSCLC) is the most predominant type of lung cancer. Lung cancer has been recognized as a complex multifactorial disease resulting from the interactions between various genetic and environmental factors. Identification of genes involved in the occurrence and development of lung cancer could contribute to further understanding of the underlying mechanisms, and even a very important additional appropriate prevention strategies and targeted treatments for reducing lung cancer burden. Many studies have suggested that key cytokines in inflammation pathways may exert important roles in the etiology of lung cancer. The aim of this study was to investigate whether common variants in inflammatory and immune response genes influence lung cancer risk in Moroccan patients. Method: Using a candidate gene approach, 6 single nucleotide polymorphisms (SNPs) in 4 genes were assessed in 117controls and 117 lung cancer patients. Genotyping was performed with the TaqMan® allelic discrimination technology. The results were analysed using SPSS 24.0 software. Results: Among the 5 studied genes, we found a significant association for the MIF (rs755622) (OR¼1.63; 95% confidence interval 1.04-2.56; p ¼0.03), IL-6 (rs2069840) (OR¼1.63; 95% confidence interval 1.08-2.47; p ¼0.01) and STAT3. No significant association was observed for the remaining SNPs in the following genes: IL17A rs7747909, IL-6R_rs2228145, IL6ST_rs2228044. Conclusion: The results founded suggest the important role of genetically determined high inflammatory response in the pathogenesis of lung cancer in the Moroccan population. Keywords: Lung cancer, Inflammatory system, Cytokines, polymorphisms P35 Treatment of Advanced NoneSmall Cell Lung Cancer (NSCLC) in Patients (P) Older Than 70
Oncologico de Cordoba, Cordoba/AR, 3 Oncologia, Instituto Oncologico de Cordoba, Cordoba/AR Background: More than 50% of advanced NSCLC patients are older than 65 years old (y), with a median age at diagnosis of 68 y. This group of patients have been usually underrepresented in clinical trials. The aim of our study is to compare whether clinical characteristics, toxicity, response rate, overall survival (OS), and progression free survival (PFS) are different in p > 70y vs. < 70y, treated with platinum based chemotherapy. Method: We reviewed the database of the Instituto Oncologico Córdoba, Argentina (IONC). Survival curves were made up by Kaplan-Maier method and compared using the log-rank test. Results: Out of 198 p; 103 p (52 %) < 70y, and 95 p (48 %) > 70y We found significant differences in OS (9.4 vs. 7.5 months, p¼0.003) and PFS (6.4 vs. 5.1 months, p¼0.002) Significant differences in OS were also found between the two groups regarding anemia, Performance status (PS) and response rate with no difference on sex and histology. Conclusion: Significant differences in OS and PFS were evident between both groups. We observed increased toxicity in p > 70y, but without greater treatment-related mortality. OS and PFS were superior in patients treated with platinum-based doublets when compared to monotherapy (according to historical records); therefore we should choose the former in elderly patients. Method: The objective of the study was to evaluate the complication rate and the diagnostic yield in computer tomography (CT)-guided core biopsies performed as standard procedure in a Thoracic Oncology Unit in Mexico. Medical journals, pathology reports and CT scans were reviewed in 164 consecutive cases, where a transthoracic core biopsy was performed between January 2013 and December 2017. A experienced radiologists member of the Thoracic Oncology Unit performed the biopsies. Of these total biopsies, 78 (47.5%) were for primary lung cancer, 91 % taken of lung lesions and 8.97% (7) All patients underwent a chest X-ray 4 hours post-biopsy and pneumothorax was seen in 8/78 (10.25%) patients even though only 1 patient (1.28%) need a chest tube insertion. Small intraparenchymal hemorrhages and hemoptysis were observed with subjective difficulty in only one case. None of patients need transfusions nor further treatment. Conclusion: A transthoracic core biopsy ensures diagnosis with a low complication rate and is suitable as an outpatient procedure. A CT-guided core biopsy is safe and applicable in our hospital in a Thoracic Oncology Unit allowing molecular analysis of biomarkers and personalized treatment. Keywords: CT-guided core biopsies, Lung cancer, Diagnostic One of the earliest responses to DSB damage is the recruitment of the repair protein, 53BP1, to DSB sites. Fluorescent-tagged antibodies specific for 53BP1 can therefore be exploited to detect DSB lesions as discrete 'fluorescent foci'. This project aimed to assess the frequency of induction and kinetics of DNA DSB repair in cells exposed to IR. Method: Primary human bronchial epithelial cells were cultured, irradiated and fixed at different time-points. Radiation induced DNA DSB were identified by immunofluorescence technique using 53BP1 as a marker protein. Images were captured and analyzed by fluorescence microscope and axiovision software. Results: After exposure to 2Gy radiation, the highest number of foci was visible within 10min (6.613foci/nucleus). The score at 10min in unirradiated and IR cells were significantly different (P¼0.00001). After then the trend declined. Average number of 53BP1 foci decreased up to 6hr (2.83 foci/nucleus at 6hr). The score at 10min was statistically different from that of 6hr (P¼0.0008). Data stayed the same from 6hr to 16hr (P at 6hr¼0.552, at 8hr¼0.615 and at 16hr¼0.768). After 16hr the foci reduced up to 24hr where it returned to nearly baseline but significant variation remained from that of unirradiated cells at 24hr-point (P¼0.001). In case of unirradiated cells, difference was not observed over the whole duration (P>0.05). Initially, after irradiation, a wide variation existed among the proportion of small, medium and large foci which was, however, getting closer with time, and by 24hr it appeared like a cluster of proportion where all fractions of foci remained the same. Conclusion: In unirradiated cells, an average of 1 DSB was seen in each nucleus for a 24hr duration whereas radiation of a dose of 2Gy produced as many as 6 DSB within 10min. DSB were quickly repaired for the first 6hr, and more than half of DSB got repaired within this period. Few DNA lesions persisted even after 24hr. Changes in the proportional size distribution of foci may be indicative of migration and clustering of radiationinduced foci representing slow DSB repair, leading to chance of chromosomal rearrangement, and subsequently increase the risk of cancer cell formation. If this hypothesis is valid and we can locate these clustering time-points specifically, specific time-points of transforming cancer cells after irradiation may be identified. 
